Cart
sales@molnova.com
ABT 102
CAS No. 808756-71-0
ABT 102( ABT-102 | ABT102 | CHEMBL398338 )
Catalog No. M27944 CAS No. 808756-71-0
ABT 102 is a selective antagonist of transient receptor potential vanilloid 1 (TRPV1) receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 258 | In Stock |
|
| 5MG | 249 | In Stock |
|
| 10MG | 369 | In Stock |
|
| 25MG | 562 | In Stock |
|
| 50MG | 770 | In Stock |
|
| 100MG | 1032 | In Stock |
|
| 200MG | 1376 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameABT 102
-
NoteResearch use only, not for human use.
-
Brief DescriptionABT 102 is a selective antagonist of transient receptor potential vanilloid 1 (TRPV1) receptor.
-
DescriptionABT 102 is a selective antagonist of transient receptor potential vanilloid 1 (TRPV1) receptor.
-
In Vitro——
-
In Vivo——
-
SynonymsABT-102 | ABT102 | CHEMBL398338
-
PathwayMembrane Transporter/Ion Channel
-
TargetTRP/TRPV Channel
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number808756-71-0
-
Formula Weight348.44
-
Molecular FormulaC21H24N4O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NC1=CC=CC2=C1C=NN2)N[C@@H]3CCC4=C3C=CC(C(C)(C)C)=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Nishiguchi G, et al. Identification of Potent, Selective, and Orally Bioavailable Small-Molecule GSPT1/2 Degraders from a Focused Library of Cereblon Modulators. J Med Chem. 2021 Jun 10;64(11):7296-7311.
molnova catalog
related products
-
MDR-652
MDR-652 is a highly specific and efficacious agonist of nonpungent transient receptor potential vanilloid 1 (TRPV1) with Ki value of 11.4 nM and 23.8 nM for hTRPV1 and rTRPV1 respectively and EC50s for hTRPV1 and rTRPV1 are 5.05 and 93 nM respectively.
-
GSK2193874
GSK2193874 was identified as a selective orally active TRPV4 blocker.
-
Vitexin
Vitexin protects brain against cerebral I/R injury, and this effect may be regulated by mitogen-activated protein kinase (MAPK) and apoptosis signaling pathways.
